Recombinant human Interferon gamma protein (Active) (ab9659)
Key features and details
- Expression system: Escherichia coli
- Purity: > 98% SDS-PAGE
- Endotoxin level: < 1.000 Eu/µg
- Active: Yes
- Suitable for: Functional Studies, SDS-PAGE, HPLC
Achieve higher consistency and quality standards with a premium grade bioactive protein
- High batch-to-batch consistency
- Optimal bioactivity
- Guaranteed identical to human native proteins
- >95% purity
- Ultra-low endotoxin levels: <0.005 Eu/µg
- Carrier and tag free
Description
-
Product name
Recombinant human Interferon gamma protein (Active)
See all Interferon gamma proteins and peptides -
Biological activity
The ED50 determined by a cytotoxicity assay using HT-29 cells is ≤ 0.05 ng/ml, corresponding to a
specific activity of ≥ 2 x 107 units/mg. -
Purity
> 98 % SDS-PAGE.
>98%% HPLC analyses. Sterile filtered. -
Endotoxin level
< 1.000 Eu/µg -
Expression system
Escherichia coli -
Accession
-
Protein length
Full length protein -
Animal free
No -
Nature
Recombinant -
-
Species
Human -
Sequence
MQDPYVKEAE NLKKYFNAGH SDVADNGTLF LGILKNWKEE SDRKIMQSQI VSFYFKLFKN FKDDQSIQKS VETIKEDMNV KFFNSNKKKR DDFEKLTNYS VTDLNVQRKA IHELIQVMAE LSPAAKTGKR KRSQMLFQGR RASQ -
Predicted molecular weight
17 kDa -
Amino acids
1 to 144
-
Associated products
-
Related Products
Specifications
Our Abpromise guarantee covers the use of ab9659 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
-
Applications
Functional Studies
SDS-PAGE
HPLC
-
Form
Lyophilized -
Concentration information loading...
Preparation and Storage
-
Stability and Storage
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Constituent: PBS
This product is an active protein and may elicit a biological response in vivo, handle with caution.
-
ReconstitutionCentrifuge vial prior to opening. Reconstitute in 100 µl 1x PBS, pH 8.0 to a concentration of 1.0 mg/ml. Do not vortex. Long term storage: Follow reconstitution with further dilution in a buffer containing a carrier protein (example; 0.1% BSA).
General Info
-
Alternative names
- IF 1
- IFG
- IFI
see all -
Function
Produced by lymphocytes activated by specific antigens or mitogens. IFN-gamma, in addition to having antiviral activity, has important immunoregulatory functions. It is a potent activator of macrophages, it has antiproliferative effects on transformed cells and it can potentiate the antiviral and antitumor effects of the type I interferons. -
Tissue specificity
Released primarily from activated T lymphocytes. -
Involvement in disease
In Caucasians, genetic variation in IFNG is associated with the risk of aplastic anemia (AA) [MIM:609135]. AA is a rare disease in which the reduction of the circulating blood cells results from damage to the stem cell pool in bone marrow. In most patients, the stem cell lesion is caused by an autoimmune attack. T-lymphocytes, activated by an endogenous or exogenous, and most often unknown antigenic stimulus, secrete cytokines, including IFN-gamma, which would in turn be able to suppress hematopoiesis. -
Sequence similarities
Belongs to the type II (or gamma) interferon family. -
Post-translational
modificationsProteolytic processing produces C-terminal heterogeneity, with proteins ending alternatively at Gly-150, Met-157 or Gly-161. -
Cellular localization
Secreted. - Information by UniProt
Images
-
All lanes : Anti-CXCL11 antibody [EPR21755-173] (ab216157) at 1/1000 dilution
Lane 1 : THP-1 (hman monocytic leukemia cell line) whole cell lysate
Lane 2 : THP-1 treated with 200 ng/ml interferon-gamma (IFN-gamma, ab9659) and 50 ng/ml lipopolysaccharide (LPS) for 24 hours, then 300 ng/ml Brefeldin A (BFA) was added to the treated cells for 20 hours, whole cell lysate
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution
Developed using the ECL technique.
Observed band size: 11 kDa why is the actual band size different from the predicted?
Exposure time: 37 secondsBlocking/Dilution: 5% NFDM/TBST
The expression profile observed is consistent with what has been described in the literature (PMID: 17142784).
-
CXCL11 was immunoprecipitated from 0.35mg of THP-1 (human monocytic leukemia cell line) whole cell lysate with ab216157 at 1/30 dilution. Western blot was performed from the immunoprecipitate using ab216157 at 1/1000 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366), was used for detection at 1/5000 dilution.
Lane 1: THP-1 (human monocytic leukemia cell line) treated with 200 ng/ml interferon-gamma (IFN-gamma, ab9659) and 50 ng/ml lipopolysaccharide (LPS) for 24 hours, then added 300 ng/ml Brefeldin A (BFA) for 20 hours, whole cell lysate 10ug (Input).
Lane 2: ab216157 IP in THP-1 treated with 200 ng/ml interferon-gamma (IFN-gamma, ab9659) and 50 ng/ml lipopolysaccharide (LPS) for 24 hours, then added 300 ng/ml Brefeldin A (BFA) for 20 hours, whole cell lysate.
Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab216157 in THP-1 treated with 200 ng/ml interferon-gamma (IFN-gamma, ab9659) and 50 ng/ml lipopolysaccharide (LPS) for 24 hours, then added 300 ng/ml Brefeldin A (BFA) for 20 hours, whole cell lysate.Blocking/Dilution buffer: 5% NFDM/TBST
-
All lanes : Anti-IP10 antibody [EPR20764] (ab214668) at 1/1000 dilution
Lane 1 : Untreated THP-1 (human monocytic leukemia cell line) culture supernatant
Lane 2 : THP-1 treated with 200 ng/ml interferon-gamma (IFN-gamma, ab9659) and 50 ng/ml lipopolysaccharides (LPS) for 24 hours, culture supernatant
Lysates/proteins at 15 µl per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution
Developed using the ECL technique.
Observed band size: 12 kDa why is the actual band size different from the predicted?
Exposure time: 15 secondsBlocking/Dilution buffer: 5% NFDM/TBST.
IP10 protein secretion can be induced by IFN-gamma treatment (PMID: 11907072).
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
References (4)
ab9659 has been referenced in 4 publications.
- Pavlinek A et al. Interferon-γ exposure of human iPSC-derived neurons alters major histocompatibility complex I and synapsin protein expression. Front Psychiatry 13:836217 (2022). PubMed: 36186864
- Warre-Cornish K et al. Interferon-? signaling in human iPSC-derived neurons recapitulates neurodevelopmental disorder phenotypes. Sci Adv 6:eaay9506 (2020). PubMed: 32875100
- Batra R et al. RNA-binding protein CPEB1 remodels host and viral RNA landscapes. Nat Struct Mol Biol 23:1101-1110 (2016). Functional Studies ; Human . PubMed: 27775709
- Wu Z et al. Oxidative stress modulates complement factor H expression in retinal pigmented epithelial cells by acetylation of FOXO3. J Biol Chem 282:22414-25 (2007). PubMed: 17558024